http://www.reportsnreports.com/Biopharm Reports Market Research Reports XML feedhttp://www.reportsnreports.com/reports/206077-life-science-software-markets-and-opportunities.htmlBiopharm Reports has carried out six studies in the life science field, which examined the use of specialist software and databases relating to the conduct of PCR, DNA sequencing, DNA microarray, flow cytometry, mass spectrometry and disease biomarker studies. These studies, which involved the participation of more than 2200 end-users in 70 countries, were carried out to assist software developers and vendors to identify market opportunities in these fields. Background The last two decades have seen unprecedented advances in technologies and applications in the life science field. Techniques such as PCR, DNA microarray, DNA sequencing, mass spectr...Mon, 24 Sep 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/206076-life-science-consumables-markets-and-opportunities.htmlThe last two decades have seen unprecedented advances in technologies and applications in the life science field. Techniques such as PCR, DNA microarray, DNA sequencing, mass spectrometry and flow cytometry have driven discoveries that have changed our understanding of the world. Today, techniques such as these are indispensable to the laboratory and by 2015, markets for these five areas alone are expected to exceed $50 billion, globally. In these and related fields, consumables are generally the second or third largest area in cost terms, after instrumentation. Biopharm Reports has carried out six studies in the life science field, which examined the use of consumables in the con...Mon, 24 Sep 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/190675-dna-sequencing-2012-market-needs-emerging-developments-and-future-use.htmlKey FindingsRoutine use: Use of flow cytometry DNA sequencing by end-users for routine (developed and validated) DNA sequencing tests, the development or validation of DNA sequencing tests and for qualitative discovery using DNA sequencing methods.Companies: End-users purchases/use  of DNA sequencing systems from more than 30 companies and their anticipated use of these systems by end-users over the next three years, each ranked according to their competitive positionDNA sequencing techniques: Current use of more than 15 DNA sequencing techniques by end-users and their anticipated use of these techniques over the next three years, each ranked acc...Sat, 15 Sep 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/191887-flow-cytometry-2012-market-needs-emerging-developments-and-future-use.htmlBiopharm Reports has carried out a study of market needs in the flow cytometry field. This study examined current techniques and applications, end-users’ plans for using flow cytometry over the next three years, as well as preferred products, purchasing and new developments. The findings of this study provide valuable support to developers and vendors operating in this field.This study involved the participation of 260 experienced flow cytometry users and decision-makers in 53 countries. It investigated current and future applications, current and future purchasing plans, research vs. clinical use across the study, new and emerging applications, end-users’ principal flow cytomet...Sat, 15 Sep 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/190676-pcr-2012-market-needs-emerging-developments-and-future-use.htmlThis study involved the participation of more than 600 experienced PCR users and decision-makers in 75 countries. It investigated PCR methods, companies and products, their strengths and weaknesses, current and future annual budgets, budget breakdown, consumables, challenges, innovation, biomarkers, bioinformatics software, sample preparation, quality control guidelines and other areas. As part of this study, PCR customers provided details of their anticipated purchases from suppliers in this field, over the period 2012 – 2015. Key FindingsRoutine use: Use of PCR by end-users for running routine (developed and validated) PCR tests, the development or valid...Mon, 20 Aug 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/191888-dna-microarray-2012-market-needs-emerging-developments-and-future-use.htmlBiopharm Reports has carried out a study of customer needs in the DNA microarray field. This examined current techniques and applications, customers’ plans for using DNA microarray over the next three years, as well as preferred products, purchasing and new developments. The findings of this study provide valuable support to developers and vendors operating in this field.This study involved the participation of more than 200 experienced DNA microarray users and decision-makers in 37 countries. It investigated DNA microarray methods, companies and products, their strengths and weaknesses, current and future annual budgets, budget breakdown, consumables, challenges, innovation, biomarke...Sat, 11 Aug 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/181605-mass-spectrometry-2012-current-practices-market-needs-emerging-developments-and-future-use-a-global-market-study.htmlMass spectrometry user practices: A detailed analysis of user practices in the mass spectrometry field, indicated by study participants. This includes the top 25 mass spectrometry companies that participants indicated had supplied systems to them, together with the top 25 ionisation methods and the top 15 ion analyzers, used by participants. Other related user data provided by participants include the top 30 currently used independent data systems and the top 75 software/databases. Participants also indicated the use of other specialist software systems, the top 15 MS configurations and the top 10 fragmentation methods, currently used.Molecule classes: ...Mon, 11 Jun 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/144888-antibiotic-resistance-2012-the-antibiotic-development-pipeline-and-strategies-to-combat-antibiotic-resistance.htmlThis report gives a comprehensive overview of global antibiotic resistance, the antibiotics pipeline and new strategies to target resistance mechanisms. It identifies 109 antibiotics in the development pipeline, approximately 70% of which are in early development (Preclinical and Phase 1). In contrast, there are just 9 candidates at Phase 3, while there are 31 at Phase 2.  These developments are being progressed by 66 companies, of which nine (14%) are major international corporations and 57 (86%) are Small/Medium Sized Enterprises (SMEs). While antibiotics are effective for the major of infections, increasing resistance in some pathogens thr...Thu, 12 Jan 2012 00:00:00 GMThttp://www.reportsnreports.com/reports/132881-vegf-inhibition-therapy-indicating-and-prognostic-biomarkers-2011.htmlVascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be iden...Mon, 24 Oct 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/131821-lung-cancer-vaccines-and-therapeutic-antibodies-pipeline-strategies-and-clinical.htmlThis report provides a comprehensive review of 27 candidate therapeutic antibodies and 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 targets, while the vaccines are directed at 24 antigens or antigen combinations. Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have sh...Sat, 01 Oct 2011 00:00:00 GMThttp://www.reportsnreports.com/reports/131822-lung-cancer-vaccines-pipeline-strategies-and-clinical.htmlThis report provides a comprehensive review of 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These vaccines are directed at 24 antigens or antigen combinations. Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while in...Sat, 01 Oct 2011 00:00:00 GMT